Sex Difference in Effects of Typical and Atypical Antipsychotics on Glucose-Insulin Homeostasis and Lipid Metabolism in First-Episode Schizophrenia
- 1 August 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 27 (4), 374-379
- https://doi.org/10.1097/jcp.0b013e3180cac8db
Abstract
The present study was to investigate the sex difference in effects of clozapine, olanzapine, risperidone, and sulpiride on glucose and lipid metabolism in first-episode schizophrenia. One hundred twelve patients with schizophrenia were assigned randomly to receive clozapine, olanzapine, risperidone, or sulpiride for 8 weeks. Planned assessments included body mass index, waist-hip ratio, fasting glucose, insulin, C-peptide, insulin resistance index (IRI), cholesterol and triglyceride levels. All measures were collected at baseline and at the end of the 8-week treatment. After treatment, waist-hip ratio and triglyceride and IRI levels of men were increased higher than that of women in clozapine and olanzapine groups. In sulpiride group, body mass index and triglyceride, insulin, and IRI levels of women increased higher than those of men. There was no significant sex difference for all assessments in risperidone group. Insulin, C-peptide, and IRI, but not fasting glucose levels, were significantly increased in the 4 groups. Cholesterol and triglyceride levels were significantly increased in the clozapine and olanzapine groups. Patients treated with clozapine and olanzapine had higher fasting insulin, C-peptide, and IRI levels than those treated with risperidone and sulpiride. These results suggest that clozapine, olanzapine, and sulpiride had effects on glucose and lipid metabolism in first-episode schizophrenia with sex difference. Clozapine and olanzapine seem to have the greatest potential to induce glucose and lipid metabolism abnormalities, and risperidone has the least.Keywords
This publication has 17 references indexed in Scilit:
- Induction of Obesity by Psychotropic DrugsAnnals of the New York Academy of Sciences, 2006
- Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychoticJournal of Psychopharmacology, 2005
- Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychoticsDiabetes Research and Clinical Practice, 2005
- Antipsychotic Medication and Diabetes MellitusrsThe Journal of Clinical Psychiatry, 2005
- Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective DisorderAmerican Journal of Psychiatry, 2004
- Weight Change after an Atypical Antipsychotic SwitchAnnals of Pharmacotherapy, 2003
- The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?European Journal of Pharmacology, 2002
- Olanzapine-Induced Weight Gain in Patients With First-Episode Schizophrenia: A Double-Blind, Placebo-Controlled Study of Fluoxetine AdditionAmerican Journal of Psychiatry, 2002
- Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: Relation to neuroleptic resistanceBiological Psychiatry, 1997
- BIOCHEMICAL DISTURBANCES IN MENTAL DISORDERSArchives of Neurology & Psychiatry, 1942